

NEW YORK, Sept. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

[Nuclear Medicine Market & Radiopharmaceuticals \[SPECT/PET Radioisotopes \(Technetium, F-18\)\], \[Beta/Alpha radiation therapy \(I131, Y-90\)\], \[Applications \(Cancer/Oncology, Cardiac\)\] & Stable Isotopes \(Deuterium, C-13\) - Global Trends & Forecast to 2017](http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-radiation-therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging) [http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-\[SPECT/PET-Radioisotopes-Technetium-F-18\]-\[Beta/Alpha-radiation-therapy-I131-Y-90\]-\[Applications-Cancer/Oncology-Cardiac\]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging](http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-radiation-therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging)

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017

The global radiopharmaceuticals market was valued at \$3.8 billion in 2012 and is poised to reach \$5.5 billion by 2017 at a CAGR of 7.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania

between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

North America is the dominant market for diagnostic radioisotopes with 49% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 90% to the global revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of

isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Global Radiopharmaceuticals Market

DiagnosticSPECTTc-99mTl-201Ga-67I-123IOthersPETF-18Rb-82IOthersTherapyBeta emittersI-131Sm-153Re-186

Y-90Lu-177IOthersAlpha emittersBrachytherapyCs-131I-125Pd-103Ir-192IOthers

Global Enriched Stable Isotopes Market

DeuteriumOxygen-18Carbon-13Nitrogen-15IOthers

Radiopharmaceutical and Stable Isotope Markets, By Geography

North AmericaEurope, including RussiaAsiaRoW (Africa, LATAM, Middle-East, Pacific countries)

1 INTRODUCTION 28

1.1 KEY TAKE-AWAYS 281.2 REPORT DESCRIPTION 281.3 MARKETS COVERED 301.4

STAKEHOLDERS 311.5 RESEARCH METHODOLOGY 321.5.1 MARKET SIZE 321.5.2
MARKET SHARE 331.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 331.5.4 KEY
DATA POINTS FROM PRIMARY SOURCES 331.5.5 ASSUMPTIONS 34

2 EXECUTIVE SUMMARY 35

3 MARKET OVERVIEW 40

3.1 DEFINITION OF RADIOPHARMACEUTICALS 413.2 EVOLUTION 413.3 MARKET
SEGMENTATION 433.3.1 RADIOPHARMACEUTICALS 433.3.2 STABLE ISOTOPES 443.4
MARKET DYNAMICS 453.4.1 DRIVERS 463.4.1.1 Increasing incidence of cancer and cardiac
ailments boosts the demand for radiopharmaceuticals 463.4.1.2 Increasing use of SPECT and
PET scans results in rise of radiopharmaceutical usage 463.4.1.3 Rising awareness of
radiopharmaceuticals to spur growth 473.4.1.4 Ready availability of radiopharmaceuticals from
cyclotrons to goad the growth 473.4.2 RESTRAINTS 473.4.2.1 Shorter half-life of
radiopharmaceuticals restricts its usage 473.4.2.2 High capital to limit the buying of scanners
483.4.2.3 Stringent regulatory guidelines and GMP to negatively impact growth 483.4.2.4
Competition from conventional diagnostic procedures 493.4.3 OPPORTUNITIES 493.4.3.1
Potential radioisotopes in the pipeline 493.4.3.2 High demand in emerging countries 503.4.3.3
Alpha radio immunotherapy-based targeted cancer treatment 503.4.3.4 Alternative diagnostic
radiopharmaceutical solutions 513.4.3.5 Cyclotron based production 51

3.4.3.6 Neurological applications 523.4.4 THREAT 523.4.4.1 Shutdown of nuclear reactors to
impact production of radioisotopes 523.5 WINNING IMPERATIVES 533.5.1 INVESTMENTS
ON NEW RADIOISOTOPES AND NOVEL APPLICATIONS 533.5.2 SHIFT TOWARDS
LEU-BASED MO-99 PRODUCTION 533.6 BURNING ISSUES 543.6.1 HIGH COST OF PET
CAMERAS 543.6.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M 543.7 MARKET SHARE
ANALYSIS 553.7.1 RADIOPHARMACEUTICALS MARKET 553.7.2 ENRICHED STABLE
ISOTOPES MARKET 583.8 VALUE CHAIN ANALYSIS 593.8.1 SPECT
(MOLYBDENUM-99/TECHNETIUM-99M) 593.8.1.1 Pricing structure in different phases of the
value chain 603.8.1.2 Cost modeling – LEU based Tc-99m production 633.8.2 PET
(FLUORINE-18) 663.8.3 STABLE ISOTOPE (DEUTERIUM) 673.9 PIPELINE ANALYSIS
693.9.1 DIAGNOSTIC RADIOISOTOPES 703.9.2 THERAPEUTIC RADIOISOTOPES 743.10
DEMAND & SUPPLY ANALYSIS 773.10.1 DEMAND FOR MO-99/TC-99M 783.10.1.1
Availability of SPECT cameras to stabilize demand 793.10.1.2 Stringent regulatory and
reimbursement procedures for alternative isotopes prevents shift from Tc-99 803.10.1.3
Emerging markets will enhance usage of Tc-99m 803.10.1.4 Potential growth of Tc-99m based
diagnostic imaging 80

.10.1.5 Shift from SPECT to PET 813.10.2 CURRENT STATUS OF MO-99 SUPPLY 813.11 STRATEGIC BENCHMARKING 863.11.1 PROCESSORS' SHIFT FROM HEU TO LEU BASED MO-99 863.11.1.1 Contract extension by Nordion with AECL & supply agreement with RIA 873.11.1.2 Agreement of Covidien & IAE POLATOM with Maria reactor 883.11.1.3 Agreement of NTP Radioisotopes with Lantheus Medical Imaging 883.11.2 SUSTAINABLE SUPPLY CHAIN BY GENERATORS 883.11.2.1 Contract extension of Lantheus Medical Imaging Inc., with NTP Radioisotopes (Pty) Ltd. 903.11.2.2 Extension of contract & acquisition by IBA Group 903.11.2.3 Acquisition of CNS Therapeutics, Inc., by Covidien, Plc. 903.11.2.4 Collaboration of NTP Radioisotopes Pty Ltd. with ANSTO 903.11.2.5 Expansion and agreement of FujiFilm Holdings Corporation 913.12 REGULATORY AFFAIRS 913.12.1 GUIDELINES IN THE U.S. 913.12.2 GUIDELINES IN EUROPE 923.12.3 REIMBURSEMENT 923.12.4 SAFETY OF PERSONNEL 933.12.5 WASTE DISPOSAL 933.12.6 EQUIPMENT & FACILITY 943.12.7 TRANSPORTATION GUIDELINES 95

4 GLOBAL RADIOPHARMACEUTICALS MARKET, BY VALUE 96

4.1 INTRODUCTION 974.2 DIAGNOSTIC MARKET 974.2.1 OPPORTUNITY MATRIX 984.2.2 SPECT RADIOPHARMACEUTICALS 994.2.2.1 Technetium-99m (Tc-99m) 1024.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes 1044.2.2.1.2 Factors affecting Technetium-99m market 1054.2.2.1.2.1 Technetium can combine with 31 different carrier molecules 1054.2.2.1.2.2 Lack of availability of technetium 1054.2.2.2 Thallium-201 (Tl-201) 1064.2.2.2.1 Tl-201 is a potential substitute for Tc-99m 1064.2.2.3 Gallium-67 (Ga-67) 1084.2.2.3.1 Fluorine-18 might seize Ga-67 market share in the near future 1084.2.2.4 Iodine (I-123) 1094.2.2.5 Others 1114.2.3 PET RADIOPHARMACEUTICALS 1124.2.3.1 Fluorine-18 1164.2.3.1.1 FDG 1164.2.3.1.2 Florbetapir 1164.2.3.1.3 Factors affecting Fluorine-18 market 118

4.2.3.1.3.1 Increasing availability of PET machines 1184.2.3.1.3.2 Rise in PET procedures increases demand for FDG 1184.2.3.1.3.3 High generation costs of FDG 1184.2.3.1.3.4 Need for speedy & efficient transportation 1184.2.3.2 Rubidium-82 (Rb-82) 1194.2.3.2.1 Bracco re-launched CardioGen-82 in February 2012 1194.2.3.3 Others 1204.2.3.3.1 Ga-68 deemed as a potential PET radioisotope 1204.3 THERAPEUTIC MARKET 1224.3.1 OPPORTUNITY MATRIX 1224.3.2 BETA EMITTERS 1234.3.2.1 Iodine-131 (I-131) 1264.3.2.2 Yttrium-90 (Y-90) 1274.3.2.2.1 Y-90 market influenced by popularity of Nordion's TheraSphere 1284.3.2.3 Samarium-153 (Sm-153) 1294.3.2.4 Rhenium-186 (Re-186) 1304.3.2.5 Lutetium-177 (Lu-177) 1314.3.2.5.1 Lu-177 is a

potential treatment option for neuroendocrine cancer 1314.3.2.6 Others 1324.3.2.6.1 Re-188 and P-33 are notable promising isotope 1334.3.3 ALPHA EMITTERS 1344.3.3.1 Radium-223 (Ra-223) & Alpharadin 1344.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC 1364.3.3.1.2 First in-class alpha pharmaceutical 1364.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy 1364.3.3.1.4 Success of Alpharadin 1374.3.3.1.5 Porter's five forces analysis 137

4.3.3.1.6 Alpharadin market potential post launch 1384.3.3.1.7 SWOT Analysis 1394.3.3.2 Actinium-225 (Ac-225) 1404.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212) 1414.3.3.4 Astatine-211 (At-211) 1414.3.3.5 Radium-224 (Ra-224) 1414.3.3.6 Thorium-227 (Th-227) 1414.3.4 BRACHYTHERAPY 1424.3.4.1 U.S. to show slow growth due to reimbursement issues 1444.3.4.2 Cesium-131 1464.3.4.3 Iodine-125 1474.3.4.4 Palladium-103 1474.3.4.5 Iridium-192 1484.3.4.6 Others 149

5 GLOBAL RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME 151

5.1 INTRODUCTION 1525.1.1 HOSPITAL BASED & LOCAL REACTORS GENERATED ISOTOPES TO BOOST THE PROCEDURAL MARKET 1525.2 DIAGNOSTIC MARKET 1555.2.1 SPECT RADIOPHARMACEUTICALS 1565.2.2 PET RADIOPHARMACEUTICALS 1585.3 THERAPEUTIC MARKET 1605.3.1 BETA EMITTERS 1615.3.2 BRACHYTHERAPY 163

6 RADIOPHARMACEUTICALS MARKET, BY APPLICATION/INDICATION 165

6.1 INTRODUCTION 1666.2 DIAGNOSTIC MARKET 1666.2.1 SPECT 1676.2.1.1 Cardiology 1686.2.1.2 Lymphoma 1706.2.1.3 Thyroid 1716.2.1.4 Neurology 1726.2.1.4.1 Alzheimer's, dementia, and Parkinson's disease drives growth of the neurology SPECT market 1726.2.1.5 Others 1736.2.2 PET APPLICATION 1746.2.2.1 Oncology 1756.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan 1756.2.2.2 Cardiology 1766.2.2.3 Neurology 1786.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 dopa) are potential substitutes of FDG F-18 1786.2.2.4 Others 1796.3 THERAPEUTIC APPLICATION 1816.3.1 THYROID 1826.3.2 BONE METASTASIS 1836.3.3 LYMPHOMA 1856.3.3.1 Novel clinical studies goading lymphoma therapy market 1856.3.4 ENDOCRINE TUMORS 1866.3.5 OTHERS 187

7 ENRICHED STABLE ISOTOPES MARKET 189

7.1 INTRODUCTION 1907.2 MARKET OVERVIEW 1917.2.1 ASIA ACCOUNTS FOR THE LARGEST MARKET SHARE 1917.3 MARKET DYNAMICS 1927.3.1 DRIVERS 1927.3.1.1 Stable isotopes are natural in origin & hence safe 1927.3.1.2 Proteomics & system biology, major factors to boost the growth of stables 1927.3.1.3 Medical applications propel stable isotopes market growth 1927.3.2 RESTRAINTS 1937.3.2.1 Harmful effects of stable isotopes affect market growth 1937.3.2.2 High cost of stables isotope 1937.4 ENRICHED STABLES MARKET, BY ISOTOPES 1947.4.1 DEUTERIUM & O-18 ARE PROMISING ISOTOPES 1947.4.2 CARBON-13 1967.4.3 DEUTERIUM 1987.4.4 OXYGEN-18 1997.4.5 NITROGEN-15 2007.4.6 OTHER STABLE ISOTOPES 2017.5 ENRICHED STABLES MARKET, BY APPLICATIONS 2027.5.1 DIAGNOSTIC & THERAPEUTIC 2037.5.2 RESEARCH 2047.5.3 PHARMACEUTICALS 2057.5.4 INDUSTRIAL SECTOR 206

8 GEOGRAPHIC ANALYSIS 208

8.1 INTRODUCTION 2098.2 DIAGNOSTIC MARKET 2098.2.1 NORTH AMERICA 2128.2.1.1 Increasing adoption of alternative production technologies to make up for the shortage of Mo-99 2138.2.2 EU ROPE 2168.2.2.1 SPECT and PET contributes almost equal in Europe 2178.2.2.2 Stringent regulations hindering market growth 2178.2.3 ASIA 2208.2.3.1 Asia promises the highest CAGR in the forecast period 2208.2.4 REST OF THE WORLD (ROW) 2238.3 THERAPY MARKET 2278.3.1 NORTH AMERICA 2308.3.1.1 Nuclear medicine research drives the beta emitters market 2328.3.2 EUROPE 2338.3.3 ASIA 2368.3.4 REST OF THE WORLD (ROW) 2398.4 ENRICHED STABLE ISOTOPES MARKET 2428.4.1 ASIA 2438.4.2 NORTH AMERICA 2448.4.3 EUROPE

2468.4.4 REST OF THE WORLD (ROW) 248

9 COMPETITIVE LANDSCAPE 251

9.1 INTRODUCTION 251
9.2 MERGERS & ACQUISITIONS 252
9.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 253
9.4 PRODUCTS LAUNCH 258
9.5 EXPANSIONS 260
9.6 OTHER DEVELOPMENTS 262
9.7 APPROVALS 266

10 COMPANY PROFILES 268 (Overview, Financials, Products & Services, Strategy, & Developments)*

10.1 COMPANIES 268
10.1.1 BRACCO IMAGING S.P.A. 268
10.1.2 CAMBRIDGE ISOTOPE LABORATORIES, INC. 271
10.1.3 CARDINAL HEALTH, INC. 275
10.1.4 COVIDIEN, PLC 282
10.1.5 ECZACIBASI-MONROL 287
10.1.6 FUJIFILM HOLDINGS CORPORATION 289
10.1.7 GE HEALTHCARE (SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 294
10.1.8 IBA GROUP 300
10.1.9 ISOTEC, INC. (SIGMA-ALDRICH) 307

10.1.10 LANTHEUS MEDICAL IMAGING, INC. 311
10.1.11 NORDION, INC. 319

10.1.12 NTP RADIOISOTOPES (PTY), LTD. 327
10.1.13 PETNET SOLUTIONS, INC. (A SUBSIDIARY OF SIEMENS MEDICAL SOLUTIONS USA, INC.) 330

10.1.14 TAIYO NIPPON SANJO CORPORATION 336
10.1.15 URENCO LIMITED 340

10.1.16 ROTEM INDUSTRIES, LTD., INC. 344
10.2 INSTITUTES 346
10.2.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 346
10.2.2 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT) 350
10.2.3 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE 352
10.2.4 INSTITUTE OF ISOTOPES CO., LTD. 355
10.2.5 INSTITUTE OF RADIOELEMENT (IRE) 358
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 (\$MILLION) 36
 TABLE 2 COST INCREASE OF TC-99M: PHASES OF SUPPLY CHAIN (%) 63
 TABLE 3 COST RANGE: NEW & MODIFIED RIG (\$MILLION) 64
 TABLE 4 COST RANGE: NEW & MODIFIED CONTAINERS (\$MILLION) 64
 TABLE 5 COST INCREASE FOR LEU-BASED CONVERSION (%) 65
 TABLE 6 COST IMPACT: PHASES OF SUPPLY CHAIN (\$/6-DAY CURIE) 65
 TABLE 7 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS, 2010 – 2017 72
 TABLE 8 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS, 2010 – 2017 76
 TABLE 9 MO-99: WEEKLY DEMAND (2011) 78
 TABLE 10 MO-99: PRODUCTION PER WEEK (2010) 81
 TABLE 11 TC-99M: PROCESSING CAPACITY (2011) 83
 TABLE 12 MO-99: POTENTIAL REACTORS 84
 TABLE 13 GLOBAL RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 (\$MILLION) 98
 TABLE 14 GLOBAL SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 101
 TABLE 15 SPECT RADIOPHARMACEUTICAL MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 102
 TABLE 16 INDICATIONS DIAGNOSED BY TC-99M 103
 TABLE 17 TC-99M MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 104
 TABLE 18 TL-201 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 107
 TABLE 19 GA-67 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 109
 TABLE 20 I-123 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 110
 TABLE 21 OTHER RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY,

2010 – 2017 (\$MILLION) 112
 TABLE 22 PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 114
 TABLE 23 GLOBAL PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 115
 TABLE 24 F-18 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 117
 TABLE 25 RB-82 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 120
 TABLE 26 OTHER PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 121
 TABLE 27 GLOBAL BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 124
 TABLE 28 BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 125
 TABLE 29 I-131 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 127
 TABLE 30 Y-90 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 128
 TABLE 31 SM-153 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 130
 TABLE 32 RE-186 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 131
 TABLE 33 LU-177 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 132
 TABLE 34 OTHER BETA-EMITTER RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 133
 TABLE 35 ALPHA EMITTERS VS BETA EMITTERS 134
 TABLE 36 HRPDA BONE METASTASIS THERAPY MARKET & ALPHARADIN ADDRESSABLE MARKET, 2015 (\$MILLION) 139
 TABLE 37 RADIOISOTOPE CHARACTERISTICS & DOSE DELIVERY OVER TIME 142
 TABLE 38 GLOBAL BRACHYTHERAPY MARKET, BY

ISOTOPE,2010 – 2017 (\$MILLION) 144

TABLE 39 BRACHYTHERAPY MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 145
 TABLE 40 CS-131 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 146
 TABLE 41 I-125 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 147
 TABLE 42 PD-103 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 148
 TABLE 43 IR-192 MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 149
 TABLE 44 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY GEOGRAPHY,2010 – 2017 (\$MILLION) 150
 TABLE 45 RADIOPHARMACEUTICAL PROCEDURES MARKET, BY GEOGRAPHY,2010 – 2017 (MILLION) 153
 TABLE 46 GLOBAL DIAGNOSTIC RADIOPHARMACEUTICAL PROCEDURES MARKET, BY TECHNOLOGY, 2010 – 2017 (MILLION) 155
 TABLE 47 GLOBAL SPECT RADIOPHARMACEUTICAL PROCEDURES MARKET,BY ISOTOPE, 2010 – 2017 (MILLION) 156
 TABLE 48 SPECT RADIOPHARMACEUTICAL PROCEDURES MARKET,BY GEOGRAPHY, 2010 – 2017 (MILLION) 157
 TABLE 49 GLOBAL PET RADIOPHARMACEUTICAL PROCEDURES MARKET,BY ISOTOPE, 2010 – 2017 (MILLION) 158
 TABLE 50 PET RADIOPHARMACEUTICAL PROCEDURES MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION) 159
 TABLE 51 GLOBAL THERAPEUTIC RADIOPHARMACEUTICAL PROCEDURES MARKET, BY TYPE, 2010 – 2017 (MILLION) 160
 TABLE 52 GLOBAL BETA EMITTER PROCEDURES MARKET, BY ISOTOPE,2010 – 2017 (MILLION) 161

TABLE 53 BETA EMITTERS RADIOPHARMACEUTICAL PROCEDURES MARKET,BY GEOGRAPHY, 2010 – 2017 (MILLION) 162
 TABLE 54 GLOBAL BRACHYTHERAPY PROCEDURES MARKET, BY ISOTOPE,2010 – 2017 (MILLION) 163
 TABLE 55 BRACHYTHERAPY RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION) 164
 TABLE 56 SPECT APPLICATION MARKET, 2010 – 2017 (\$MILLION) 168
 TABLE 57 CARDIOLOGY SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 169
 TABLE 58 LYMPHOMA SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 170
 TABLE 59 THYROID SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 172
 TABLE 60 NEUROLOGY SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 173
 TABLE 61 OTHER SPECT APPLICATIONS MARKET, BY GEOGRAPHY,2010 – 2017 (\$MILLION) 174
 TABLE 62 GLOBAL PET APPLICATION MARKET, 2010 – 2017 (\$MILLION) 175
 TABLE 63 ONCOLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 176
 TABLE 64 CARDIOLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 177
 TABLE 65 NEUROLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 179
 TABLE 66 OTHER PET APPLICATIONS MARKET, BY GEOGRAPHY,2010 – 2017 (\$MILLION) 180
 TABLE 67 GLOBAL RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC APPLICATIONS,2010 – 2017 (\$MILLION) 181
 TABLE 68 RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC APPLICATIONS, BY GEOGRAPHY,2010 – 2017 (\$MILLION) 182

TABLE 69 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR THYROID APPLICATION, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 183
 TABLE 70 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR BONE METASTASIS APPLICATION, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 184
 TABLE 71 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR LYMPHOMA APPLICATION, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 186
 TABLE 72 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR ENDOCRINE APPLICATION, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 187
 TABLE 73 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 188
 TABLE 74 GLOBAL STABLE ISOTOPE MARKET, 2010 – 2017 (\$MILLION) 194
 TABLE 75 STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 195
 TABLE 76 CARBON STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 197
 TABLE 77 DEUTERIUM STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 198
 TABLE 78 OXYGEN STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 199
 TABLE 79 NITROGEN STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 200
 TABLE 80 OTHER STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 201
 TABLE 81 GLOBAL ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION, 2010 – 2017 (\$MILLION) 202

TABLE 82 STABLE ISOTOPES MARKET FOR MEDICAL APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 203
 TABLE 83 STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 205
 TABLE 84 STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 206
 TABLE 85 STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 207
 TABLE 86 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 210
 TABLE 87 SPECT RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 211
 TABLE 88 PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 212
 TABLE 89 NORTH AMERICA: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 (\$MILLION) 214
 TABLE 90 NORTH AMERICA: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 215
 TABLE 91 NORTH AMERICA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 216
 TABLE 92 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 (\$MILLION) 218
 TABLE 93 EUROPE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 219
 TABLE 94 EUROPE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 220
 TABLE 95 ASIA: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 (\$MILLION) 221
 TABLE 96 ASIA: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 222
 TABLE 97 ASIA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 223
 TABLE 98 ROW: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY, 2010 – 2017 (\$MILLION) 224

TABLE 99 ROW: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,2010 – 2017 (\$MILLION) 225TABLE 100 ROW: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,2010 – 2017 (\$MILLION) 226TABLE 101 BETA EMITTER MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 228TABLE 102 BRACHYTHERAPY MARKET, BY GEOGRAPHY, 2010 – 2017 (\$MILLION) 229TABLE 103 NORTH AMERICA: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 (\$MILLION) 230TABLE 104 NORTH AMERICA: BRACHYTHERAPY MARKET, BY ISOTOPE,2010 – 2017 (\$MILLION) 231TABLE 105 NORTH AMERICA: BETA EMITTER MARKET, BY ISOTOPE,2010 – 2017 (\$MILLION) 232TABLE 106 EUROPE: RADIOPHARMACEUTICAL MARKET, BY THERAPY,2010 – 2017 (\$MILLION) 233TABLE 107 EUROPE: BRACHYTHERAPY MARKET, BY ISOTOPE,2010 – 2017 (\$MILLION) 234TABLE 108 EUROPE: BETA EMITTER MARKET, BY ISOTOPE,2010 – 2017 (\$MILLION) 235TABLE 109 ASIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,2010 – 2017 (\$MILLION) 236TABLE 110 ASIA: BRACHYTHERAPY MARKET, BY ISOTOPE,2010 – 2017 (\$MILLION) 237TABLE 111 ASIA: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 238TABLE 112 ROW: RADIOPHARMACEUTICAL MARKET, BY THERAPY,2010 – 2017 (\$MILLION) 239

TABLE 113 ROW: BRACHYTHERAPY MARKET, BY ISOTOPE,2010 – 2017 (\$MILLION) 240TABLE 114 ROW: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 (\$MILLION) 241TABLE 115 ENRICHED STABLE ISOTOPE MARKET, BY GEOGRAPHY,2010 – 2017 (\$MILLION) 242TABLE 116 ASIA: STABLE ISOTOPE MARKET, 2010 – 2017 (\$MILLION) 243TABLE 117 ASIA: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,2010 – 2017 (\$MILLION) 244TABLE 118 NORTH AMERICA: ENRICHED STABLE ISOTOPE MARKET,2010 – 2017 (\$MILLION) 245TABLE 119 NORTH AMERICA: STABLE ISOTOPE MARKET, BY APPLICATION,2010 – 2017 (\$MILLION) 246TABLE 120 EUROPE: ENRICHED STABLE ISOTOPE MARKET,2010 – 2017 (\$MILLION) 247TABLE 121 EUROPE: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,2010 – 2017 (\$MILLION) 248TABLE 122 ROW: ENRICHED STABLE ISOTOPE MARKET, 2010 – 2017 (\$MILLION) 249TABLE 123 ROW: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,2010 – 2017 (\$MILLION) 250TABLE 124 MERGERS & ACQUISITIONS, 2010 – 2012 252TABLE 125 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013 253TABLE 126 PRODUCTS LAUNCH, 2010 – 2013 258TABLE 127 EXPANSIONS, 2010 – 2012 260TABLE 128 OTHER DEVELOPMENTS, 2010 – 2012 262TABLE 129 APPROVALS, 2010 – 2011 266TABLE 130 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,BY SEGMENT, 2010 – 2012 (\$MILLION) 272TABLE 131 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,BY GEOGRAPHY, 2010 – 2012 (\$MILLION) 273TABLE 132 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,2010 – 2012 (\$MILLION) 276

TABLE 133 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012

(\$MILLION) 277TABLE 134 COVIDIEN, PLC: TOTAL REVENUE AND R&D EXPENDITURE,2010 – 2012 (\$MILLION) 283TABLE 135 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT,2010 – 2012 (\$MILLION) 283TABLE 136 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 (\$MILLION) 285TABLE 137 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT,2010 – 2012 (\$MILLION) 291TABLE 138 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 (\$MILLION) 291TABLE 139 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 (\$BILLION) 295TABLE 140 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT,2009 – 2011 (\$BILLION) 295TABLE 141 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 (\$BILLION) 296TABLE 142 IBA GROUP: MARKET REVENUE, BY SEGMENT, 2009 – 2011 (\$MILLION) 302TABLE 143 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 (\$MILLION) 303TABLE 144 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 (\$MILLION) 308TABLE 145 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 (\$MILLION) 309

TABLE 146 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 (\$MILLION) 313TABLE 147 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 (\$MILLION) 314TABLE 148 NORDION, INC.: TOTAL REVENUE, BY SEGMENT,2010 – 2012 (\$MILLION) 321TABLE 149 NORDION, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 (\$MILLION) 321TABLE 150 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 (\$MILLION) 331TABLE 151 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 (\$MILLION) 331TABLE 152 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 (\$MILLION) 332TABLE 153 TAIYO NIPPON SAN SO, CORP.: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 (\$MILLION) 338

LIST OF FIGURES

FIGURE 1 GLOBAL RADIOPHARMACEUTICAL MARKET, BY SEGMENT, 2010 – 2017 37FIGURE 2 RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2012 (\$MILLION) 38FIGURE 3 GLOBAL STABLE ISOTOPES MARKET, 2012 – 2017 (\$MILLION) 39FIGURE 4 EVOLUTION OF RADIOPHARMACEUTICALS 41FIGURE 5 RADIOPHARMACEUTICALS MARKET SEGMENTATION 43FIGURE 6 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION 44FIGURE 7 MARKET DYNAMICS 45FIGURE 8 RADIOPHARMACEUTICALS: MARKET SHARE ANALYSIS,BY KEY PLAYERS, 2012 55FIGURE 9 ENRICHED STABLE ISOTOPE: MARKET SHARE ANALYSIS,BY KEY PLAYERS, 2012 58FIGURE 10 MO-99/TC-99M: SUPPLY CHAIN 59FIGURE 11 TC-99M: SUPPLY CHAIN PARTICIPANTS 61FIGURE 12 TC-99M: VALUE CHAIN ANALYSIS 61FIGURE 13 TC-99M: PRICING FACTORS 66FIGURE 14 FLUORINE-18: SUPPLY CHAIN 67FIGURE 15 DEUTERIUM: SUPPLY CHAIN 68FIGURE 16 MAJOR SPONSORS, CLINICAL STUDIES, 2010 – 2017 69FIGURE 17 CLINICAL TRIALS FOR DIAGNOSTIC &

THERAPEUTIC APPLICATIONS OF RADIOISOTOPES, BY PHASE, 2010 – 2017 70
 FIGURE 18 CLINICAL TRIALS (PHASE III & IV) FOR DIAGNOSTIC RADIOISOTOPES, 2010 – 2017 71
 FIGURE 19 UPCOMING RADIOPHARMACEUTICAL APPLICATIONS (DIAGNOSIS), 2010 – 2017 71
 FIGURE 20 CLINICAL TRIALS (PHASE III & IV) FOR THERAPEUTIC RADIOISOTOPES, 2010 – 2017 74
 FIGURE 21 UPCOMING RADIOPHARMACEUTICAL APPLICATIONS (THERAPY), 2010 – 2017 75
 FIGURE 22 MO-99 DEMAND (SIX DAYS CURIE) PER WEEK, 2012 VS 2030 78
 FIGURE 23 MO-99: SUPPLY VS DEMAND ANALYSIS, 2010 – 2020 85
 FIGURE 24 SHIFT TOWARDS LEU FROM HEU 86
 FIGURE 25 SUSTAINABLE SUPPLY CHAIN & LOGISTICS 89
 FIGURE 26 OPPORTUNITY MATRIX: GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET (2012) 99
 FIGURE 27 SPECT RADIOISOTOPE MARKET SHARE (2012) 100
 FIGURE 28 PET RADIOPHARMACEUTICALS MARKET SHARE (2012) 113
 FIGURE 29 OPPORTUNITY MATRIX: GLOBAL THERAPEUTIC RADIOPHARMACEUTICALS MARKET (2012) 123
 FIGURE 30 RA-223 DECAY CHAIN 135
 FIGURE 31 PORTER'S FIVE FORCES ANALYSIS FOR ALPHARADIN 138

FIGURE 32 SWOT ANALYSIS OF ALPHARADIN 140
 FIGURE 33 GLOBAL RADIOPHARMACEUTICAL PROCEDURES MARKET, 2012 154
 FIGURE 34 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY INDICATION (2012) 167
 FIGURE 35 KEY GROWTH STRATEGIES, 2010 – 2013 251
 FIGURE 36 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 (\$BILLION) 272
 FIGURE 37 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 – 2012 (\$BILLION) 276
 FIGURE 38 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE, 2010 – 2012 (\$MILLION) 284
 FIGURE 39 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 (\$BILLION) 290
 FIGURE 40 IBA GROUP: TOTAL MARKET REVENUE, 2009 – 2011 (\$MILLION) 301
 FIGURE 41 ISOTEC INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 (\$BILLION) 308
 FIGURE 42 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 (\$MILLION) 312
 FIGURE 43 NORDION, INC.: TOTAL MARKET REVENUE, 2010 – 2012 (\$MILLION) 320
 FIGURE 44 TAIYO NIPPON SANCO, CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 (\$BILLION) 337
 FIGURE 45 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 – 2011 (\$BILLION) 341

To order this report: [Nuclear Medicine Market & Radiopharmaceuticals \[SPECT/PET Radioisotopes \(Technetium, F-18\)\], \[Beta/Alpha radiation therapy \(I131, Y-90\)\], \[Applications \(Cancer/Oncology, Cardiac\)\] & Stable Isotopes \(Deuterium, C-13\) - Global Trends & Forecast to 2017](http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-radiation-therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging)
[http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-\[SPECT/PET-Radioisotopes-Technetium-F-18\]-\[Beta/Alpha-radiation-therapy-I131-Y-90\]-\[Applications-Cancer/Oncology-Cardiac\]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging](http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-radiation-therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging)

Written by Australian Business

Contact Clare: clare@reportlinker.com US:
(339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

RELATED LINKS <http://www.reportlinker.com>